MAPK8IP1: A Protein Regulator of MAPK Signaling (G9479)

Target Name: MAPK8IP1

NCBI ID: G9479

MAPK8IP1: A Protein Regulator of MAPK Signaling

MAPK8IP1, also known as Mitogen-Activated Protein Kinase 8-Interacting Protein 1, is a protein that is expressed in various tissues and cell types in the human body. It is a key regulator of the mitogen-activated protein kinase (MAPK) signaling pathway, which is involved in a wide range of cellular processes, including cell growth, differentiation, and inflammation.

MAPK8IP1 is a 21-kDa protein that is composed of 155 amino acid residues. It is expressed in a variety of tissues, including skeletal muscles, heart, liver, and brain. It is also found in the plasma, which suggests that it may have a role in regulating cellular processes outside of cells.

The MAPK8IP1 gene was identified and sequenced in 2008, and it has since been shown to be involved in a number of cellular processes. For example, MAPK8IP1 has been shown to play a role in cell growth and differentiation, and it has been shown to be involved in the regulation of cell survival and apoptosis.

MAPK8IP1 is also known as a potential drug target, or biomarker, due to its involvement in the MAPK signaling pathway. The MAPK signaling pathway has been implicated in a wide range of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. By targeting MAPK8IP1, researchers may be able to develop new treatments for these diseases.

One way that researchers are studying MAPK8IP1 is to use it as a drug target. Researchers have shown that inhibiting MAPK8IP1 can lead to a variety of cellular and molecular changes, including a reduction in cell proliferation and a decrease in the formation of new blood vessels. This suggests that MAPK8IP1 may be an effective target for cancer and other diseases.

Another way that researchers are studying MAPK8IP1 is to use it as a biomarker. Researchers have shown that MAPK8IP1 is expressed in a variety of tissues and can be used as a marker for cancer and other diseases. For example, they have used MAPK8IP1 as a biomarker to diagnose and monitor the effectiveness of cancer treatments.

MAPK8IP1 is also being studied as a potential therapeutic agent for a variety of diseases. For example, researchers have shown that inhibiting MAPK8IP1 can be an effective way to treat neurodegenerative diseases, such as Alzheimer's and Parkinson's disease. They have also shown that inhibiting MAPK8IP1 can be an effective way to treat autoimmune disorders, such as rheumatoid arthritis and lupus.

In conclusion, MAPK8IP1 is a protein that is involved in the regulation of the MAPK signaling pathway. It is expressed in a variety of tissues and has been shown to play a role in a wide range of cellular processes. MAPK8IP1 is also being studied as a potential drug target and biomarker, and it is being investigated as a therapeutic agent for a variety of diseases. Further research is needed to fully understand the role of MAPK8IP1 in cellular processes and its potential as a drug and biomarker.

Protein Name: Mitogen-activated Protein Kinase 8 Interacting Protein 1

Functions: The JNK-interacting protein (JIP) group of scaffold proteins selectively mediates JNK signaling by aggregating specific components of the MAPK cascade to form a functional JNK signaling module. Required for JNK activation in response to excitotoxic stress. Cytoplasmic MAPK8IP1 causes inhibition of JNK-regulated activity by retaining JNK in the cytoplasm and inhibiting JNK phosphorylation of c-Jun. May also participate in ApoER2-specific reelin signaling. Directly, or indirectly, regulates GLUT2 gene expression and beta-cell function. Appears to have a role in cell signaling in mature and developing nerve terminals. May function as a regulator of vesicle transport, through interactions with the JNK-signaling components and motor proteins. Functions as an anti-apoptotic protein and whose level seems to influence the beta-cell death or survival response. Acts as a scaffold protein that coordinates with SH3RF1 in organizing different components of the JNK pathway, including RAC1 or RAC2, MAP3K11/MLK3 or MAP3K7/TAK1, MAP2K7/MKK7, MAPK8/JNK1 and/or MAPK9/JNK2 into a functional multiprotein complex to ensure the effective activation of the JNK signaling pathway. Regulates the activation of MAPK8/JNK1 and differentiation of CD8(+) T-cells

More Common Targets